Shots:

• The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701- Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for pancreatic cancer

• In Nov-2017- BTI and Nektar Therapeutics initially collaborated for preclinical development and expand their collaboration on 24 Sept-2018 for novel triple combination therapy

• Under the collaboration- BTI will be responsible for the clinical development & Nektar will equally share development cost of novel triple combination therapy

Ref: Ascendis Pharma | Image: Merck KGaA